TK1在实体肿瘤中诊断和判断预后的应用进展  

The progress of diagnosis and prognosis of thymidine kinase I in solid tumors

作　　者：郑梦颖[1] 郑玲[1] 贾健锋[1] 

机构地区：[1]成都大学附属医院肿瘤科,四川成都610082

出　　处：《医药前沿》2017年第17期5-8,共4页Journal of Frontiers of Medicine

摘　　要：胸苷激酶1（Thymidine kinasel，TK1）是一种国际公认的细胞增殖标志物，在肿瘤的早期筛查、疗效监控、预后与复发评估中显示着越来越重要的作用。TK在人类细胞中以两种同工酶形式存在：细胞质胸苷激酶（TK1）和线粒体胸苷激酶（TK2），而只有TK1是DNA合成过程中的关键酶之一，其在ATP和Mg2＋参与下，催化脱氧胸苷（TdR）为脱氧1-磷酸胸苷酸（dTMP），由于TK1的含量与DNA的合成呈正相关，因此TK1也被称为S期特殊标志激酶。大量临床研究显示，TK1在实体恶性肿瘤早期发生发展中都有升高，检测组织和血清中TK1活性及含量的变化可作为肿瘤细胞增殖水平的监控指标，本文就目前TK1在各实体瘤中诊断和判断预后的研究进展作一综述。Thymidine kinase 1 is an internationally recognized cell proliferation markers, its therapeutic effect monitoring and prognosis and recurrence is showing more and more important role in the appraisal. TK in human cells in the form of two kinds of isozyrne exists： the cytoplasm thymidine kinase （TK1） and mitochondrial thymidine kinase （TK2）, while only TK1 is one of the key enzymes in the process of DNA synthesis, the ATP and Mg2＋ catalytic deoxidization thymidine （TdR） for 1 - phosphoric acid deoxidizing thymidylic acid （dTMP）, as a result of the TK1 content and DNA synthesis were positively correlated, so TK1 also referred to as the special symbol kinase S period. A large number of clinical studies have shown that TK1 in entity has increased in early development of malignancy, testing organizations and the change of serum TK1 activity and content can be used for monitoring level of tumor cell proliferation index.

关 键 词：TK1 实体肿瘤 诊断 预后 

分 类 号：R730.3[医药卫生—肿瘤]